Status:
RECRUITING
Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients
Lead Sponsor:
Mostafa Bahaa
Collaborating Sponsors:
Dalia Naser Abdel-Sadek Safa , Faculty of Pharmacy, Tanta University
Sahar Mohamed Elhaggar, Faculty of Pharmacy, Tanta University
Conditions:
Gout
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\>6.8 mg/dl) is a requirement for...
Eligibility Criteria
Inclusion
- Males or females aged \< 18 years.
- All patients are diagnosed to have gout with serum uric acid \< 7 mg/dl.
- All patients are diagnosed to have obesity with body mass index (BMI) ≥ 30 kg/m2.
Exclusion
- The presence of any type of diabetes mellitus.
- Patients with drug-induced hyperuriceamia (those taking anti-TB agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol).
- Non-obese patients with BMI \>30 kg/m2.
- Pregnant or lactating women.
Key Trial Info
Start Date :
May 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06995339
Start Date
May 30 2025
End Date
December 20 2026
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mostafa Bahaa
Damietta, New Damietta, Egypt, 34518